Effect of prophylactic measures on the microbial flora of patients in protected environment units.
D000293:Adolescent; D000328:Adult; D000392:Air Movements; D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000517:prevention & control*; D001437:Bacteriuria; D002648:Child; D004423:Ear / Q000382:microbiology; D005243:Feces / Q000382:microbiology; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000517:prevention & control*; D009666:Nose / Q000382:microbiology; D009761:Nystatin / Q000627:therapeutic use; D010303:Paromomycin / Q000627:therapeutic use; D010357:Patient Isolators; D010614:Pharynx / Q000382:microbiology; D011113:Polymyxins / Q000627:therapeutic use; D012867:Skin / Q000382:microbiology; D014621:Vagina / Q000382:microbiology; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D005839:Gentamicins; D011113:Polymyxins; D009761:Nystatin; D010303:Paromomycin; D014640:Vancomycin; D000666:Amphotericin B